Thursday, June 22, 2017 10:11:08 AM
22nd Century Receives Guidance from FDA on Phase III Clinical Trials
Today 9:55 AM ET (Business Wire)
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on June 20, 2017, the Company and its wholly owned subsidiary, Heracles Pharmaceuticals, participated in a meeting with the multi-discipline review team in the Division of Anesthesia, Analgesia, and Addiction Products at the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) regarding the Company's Investigational New Drug Application (IND) for 22nd Century's X-22 prescription-based smoking cessation product in development so that it may become available for doctors to prescribe to help their patients to stop smoking. The meeting with the FDA/CDER was very positive and productive. FDA/CDER and the Company will work to reach agreement on the Company's design and implementation of two parallel, Phase III clinical trials to be conducted by the Company in various parts of the United States to show that the Company's X-22 prescription-based smoking cessation product will result in a more robust quit rate in smoking as compared to existing smoking cessation products that are already in the market in the U.S. The Company believes that it will be able to achieve such robust results.
Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group, stated, "The mission of our Company is to reduce the harm caused by smoking and we believe that we can help smokers to successfully stop smoking through the use of our novel X-22 smoking cessation product in development. We look forward to working collaboratively and closely with the FDA during 2017 regarding the approval of important aspects of the two parallel, Phase III clinical trials on X-22 that we intend to commence in the first half of 2018, subject to our determination of whether we will use funds from a third-party or Company funds to conduct such clinical trials. The public health implications of a smoking cessation product that is more robust in effectiveness than other existing smoking cessation products is enormous. We look forward to continuing to work closely with the FDA on this very important public health matter."
About 22nd Century Group, Inc.
Recent XXII News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/25/2024 09:00:31 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 10:21:11 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/16/2024 09:26:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 05:31:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 01:14:57 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/05/2024 08:17:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 01:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 01:00:13 PM
- Form 253G3 - • Edgar (US Regulatory) • 08/16/2024 09:27:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:25:39 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 08/14/2024 04:15:01 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 10:05:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:00:20 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/08/2024 09:00:39 PM
- Form 1-A - Offering Statement [Regulation A] • Edgar (US Regulatory) • 08/02/2024 09:07:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:46:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 08:30:17 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/10/2024 09:01:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:05:23 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 10:08:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 09:22:05 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/09/2024 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:30:52 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM